Explore more publications!
Massachusetts Weekly
Got News to Share?

Massachusetts Weekly: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Weekly.

October 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

Press releases published on December 5, 2025

Alterity Capital Invests in New England’s Leading Pickleball Company
December 5, 2025

Alterity Capital Invests in New England’s Leading Pickleball Company

Indeterminate EIN Presswire
Musings from the Magic Desk by Boston-Based Author Leslie Medalie
December 5, 2025

Musings from the Magic Desk by Boston-Based Author Leslie Medalie

Indeterminate EIN Presswire
Next Level Now Becomes Women-Owned Under CEO Brandi Bonds; Sonja Fridell Pomerleau Named Equity Partner & COO
December 5, 2025

Next Level Now Becomes Women-Owned Under CEO Brandi Bonds; Sonja Fridell Pomerleau Named Equity Partner & COO

Indeterminate EIN Presswire
Jedox named a Leader in the 2025 Gartner® Magic Quadrant™ for Financial Planning Software
December 5, 2025

Jedox named a Leader in the 2025 Gartner® Magic Quadrant™ for Financial Planning Software

Indeterminate EIN Presswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 5, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Spyre Therapeutics Announces Grants of Inducement Awards
December 5, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

Indeterminate GlobeNewswire
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025
December 5, 2025

Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025

Indeterminate GlobeNewswire
Hingham Savings Authorizes Stock Repurchase Program
December 5, 2025

Hingham Savings Authorizes Stock Repurchase Program

Indeterminate GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 5, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
December 5, 2025

KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire
Musical & Artistic Vibes From Across the Globe at Indigenous Holiday Market
December 5, 2025

Musical & Artistic Vibes From Across the Globe at Indigenous Holiday Market

Indeterminate EIN Presswire
1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration
December 5, 2025

1910 Publishes CANDID-CNS™, an AI Model That Unlocks Beyond Rule of 5 Chemical Space and Stereochemistry to Predict Blood–Brain Barrier Penetration

Indeterminate GlobeNewswire
Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF
December 5, 2025

Accendatech US comments on the recent setback in phase 2 study to evaluate STAT3 as therapeutic target and other drug development strategies such as AI and precision medicine to treat patients with IPF

Indeterminate GlobeNewswire
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
December 5, 2025

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Indeterminate GlobeNewswire
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures
December 5, 2025

Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Indeterminate GlobeNewswire
Stran & Company Launches Client-Branded Online Gifting Platform; First Deployment Begins with One of the World’s Largest Audit, Tax, and Advisory Firms
December 5, 2025

Stran & Company Launches Client-Branded Online Gifting Platform; First Deployment Begins with One of the World’s Largest Audit, Tax, and Advisory Firms

Indeterminate GlobeNewswire
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
December 5, 2025

Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition

Indeterminate GlobeNewswire
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 5, 2025

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire
Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock
December 5, 2025

Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions